Drug
Bgb A425
Bgb A425: highest development phase Phase 2, developed by BeiGene. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| BGB-A425 NCT05909904 | Phase 2 | Head and Neck Squamous Cell Carcinoma |
Latest
No recent events.
Follow Bgb A425 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.